Porcilis PCV M Hyo
porcine circovirus type 2 ORF2 subunit antigen / Mycoplasma hyopneumoniae inactivated
An overview of Porcilis PCV M Hyo and why it is authorised in the EU
Porcilis PCV M Hyo is a veterinary vaccine used to protect pigs against two separate infections, caused by porcine circovirus and Mycoplasma hyopneumoniae.
- Porcine circovirus type 2 (PCV2) infections can produce clinical signs such as weight loss or failure to grow, enlarged lymph nodes, difficulty in breathing, diarrhoea, pale skin and jaundice (yellowing of the skin).
- Infection with the bacterium Mycoplasma hyopneumoniae in pigs causes a disease of the airways called enzootic pneumonia. Affected pigs often have a cough and fail to thrive.
Porcilis PCV M Hyo contains porcine circovirus type 2 (PCV2) subunit antigen (a protein derived from part of the virus) and an inactivated (killed) strain of Mycoplasma hyopneumoniae bacteria.
Porcilis PCV M Hyo : EPAR - Medicine overview (PDF/89.36 KB)
First published: 14/11/2014
Last updated: 04/09/2018
Porcilis PCV M Hyo
|Agency product number||
Porcine circovirus type 2 (PCV2) ORF2 subunit antigen, Mycoplasma hyopneumoniae J strain inactivated
|International non-proprietary name (INN) or common name||
Pigs (for fattening)
|Anatomical therapeutic chemical veterinary (ATCvet) codes||
Intervet International B.V.
|Date of issue of marketing authorisation valid throughout the European Union||
Wim de Körverstraat 35
15/06/2020 Porcilis PCV M Hyo - EMEA/V/C/003796 - IA/0014
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Immunologicals for suidae
Inactivated viral and inactivated bacterial vaccines
For the active immunisation of pigs to reduce viraemia, virus load in lungs and lymphoid tissues, virus shedding caused by porcine circovirus type 2 (PCV2) infection, and severity of lung lesions caused by Mycoplasma hyopneumoniae infection. To reduce the loss of daily weight gain during the finishing period in face of infections with Mycoplasma hyopneumoniae and/or PCV2 (as observed in field studies)